Early vasopressor administration in pediatric blunt liver and spleen injury: An ATOMAC+ study.


Journal

Journal of pediatric surgery
ISSN: 1531-5037
Titre abrégé: J Pediatr Surg
Pays: United States
ID NLM: 0052631

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 15 04 2020
revised: 23 06 2020
accepted: 02 07 2020
pubmed: 12 8 2020
medline: 25 6 2021
entrez: 12 8 2020
Statut: ppublish

Résumé

No prior studies have examined the outcomes of early vasopressor use in children sustaining blunt liver or spleen injury (BLSI). A planned secondary analysis of vasopressor use from a 10-center, prospective study of 1004 children with BLSI. Inverse probability of treatment weighting (IPTW) was used to compare patients given vasopressors <48 h after injury to controls based on pretreatment factors. A logistic regression was utilized to assess survival associated with vasopressor initiation factors on mortality and nonoperative management (NOM) failure. Of 1004 patients with BLSI, 128 patients were hypotensive in the Pediatric Trauma Center Emergency Department (ED); 65 total patients received vasopressors. Hypotension treated with vasopressors was associated with a sevenfold increase in mortality (AOR = 7.6 [p < 0.01]). When excluding patients first given vasopressors for cardiac arrest, the risk of mortality increased to 11-fold (AOR = 11.4 [p = 0.01]). All deaths in patients receiving vasopressors occurred when started within the first 12 h after injury. Vasopressor administration at any time was not associated with NOM failure. After propensity matching, early vasopressor use for hypotension in the ED was associated with an increased risk of death, but did not increase the risk of failure of NOM. Level III prognostic and epidemiological, prospective.

Sections du résumé

BACKGROUND BACKGROUND
No prior studies have examined the outcomes of early vasopressor use in children sustaining blunt liver or spleen injury (BLSI).
METHODS METHODS
A planned secondary analysis of vasopressor use from a 10-center, prospective study of 1004 children with BLSI. Inverse probability of treatment weighting (IPTW) was used to compare patients given vasopressors <48 h after injury to controls based on pretreatment factors. A logistic regression was utilized to assess survival associated with vasopressor initiation factors on mortality and nonoperative management (NOM) failure.
RESULTS RESULTS
Of 1004 patients with BLSI, 128 patients were hypotensive in the Pediatric Trauma Center Emergency Department (ED); 65 total patients received vasopressors. Hypotension treated with vasopressors was associated with a sevenfold increase in mortality (AOR = 7.6 [p < 0.01]). When excluding patients first given vasopressors for cardiac arrest, the risk of mortality increased to 11-fold (AOR = 11.4 [p = 0.01]). All deaths in patients receiving vasopressors occurred when started within the first 12 h after injury. Vasopressor administration at any time was not associated with NOM failure.
CONCLUSION CONCLUSIONS
After propensity matching, early vasopressor use for hypotension in the ED was associated with an increased risk of death, but did not increase the risk of failure of NOM.
LEVEL OF EVIDENCE METHODS
Level III prognostic and epidemiological, prospective.

Identifiants

pubmed: 32778447
pii: S0022-3468(20)30485-1
doi: 10.1016/j.jpedsurg.2020.07.007
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

500-505

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

David M Notrica (DM)

Phoenix Children's Hospital. Electronic address: dnotrica@phoenixchildrens.com.

Bethany L Sussman (BL)

Phoenix Children's Hospital.

Lois W Sayrs (LW)

Phoenix Children's Hospital.

Shawn D St Peter (SD)

Children's Mercy Kansas City.

R Todd Maxson (RT)

Arkansas Children's Hospital.

Adam C Alder (AC)

Children's Medical Center part of Children's Health(SM).

James W Eubanks (JW)

Le Bonheur Children's Hospital.

Jeremy J Johnson (JJ)

The Children's Hospital at OU Medical Center.

Daniel J Ostlie (DJ)

Phoenix Children's Hospital; American Family Children's Hospital.

Todd Ponsky (T)

Akron Children's Hospital.

Jessica A Naiditch (JA)

Dell Children's Medical Center.

Charles M Leys (CM)

American Family Children's Hospital.

Karla A Lawson (KA)

Dell Children's Medical Center.

Cynthia Greenwell (C)

Children's Medical Center part of Children's Health(SM).

Amina Bhatia (A)

Children's Healthcare of Atlanta.

Nilda M Garcia (NM)

Dell Children's Medical Center.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH